Thermo Fisher Scientific Inc.
A global life sciences company that makes the instruments, reagents, and consumables used in biological research, drug and vaccine discovery, and disease diagnosis. Its brands include Thermo Scientific, Applied Biosystems, Invitrogen, and Fisher Scientific, and it also runs outsourced pharma services through Patheon and PPD, helping develop and manufacture medicines and run clinical trials.
Granted 377.9K · Sold 403.8K
Granted 183.5K · Sold 108.7K
Granted 1.4K
Granted 53.0K · Sold 41.6K
Granted 22.7K · Sold 9.2K
Granted 21.7K · Sold 14.1K
Granted 40.4K · Sold 32.1K
Granted 1.4K · Bought 20 · Sold 16
Granted 40.6K · Sold 40.7K
Granted 24.0K · Sold 24.3K
Granted 1.4K
Granted 1.4K
Granted 6.4K
Granted 1.4K
Granted 1.4K
Granted 904
Granted 3.0K · Sold 1.2K
Granted 1.4K · Sold 164
Granted 1.4K
Granted 1.4K
Granted 1.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Casper Marc NChairman & CEO, Director · 402 transactions | -22.8% | 154.8K | 377.9K | — | 403.8K |
| Lagarde MichelExecutive Vice President · 30 transactions | +377.9% | 85.2K | 183.5K | — | 108.7K |
| Sperling Scott MDirector · 4 transactions | -4.1% | 69.5K | 1.4K | — | — |
| Williamson StephenRetiring Sr. VP and CFO · 29 transactions | — | 45.2K | 53.0K | — | 41.6K |
| Pettiti GianlucaPresident & COO · 35 transactions | +42.7% | 25.1K | 22.7K | — | 9.2K |
| Shafer Michael DExecutive Vice President · 24 transactions | — | 20.9K | 21.7K | — | 14.1K |
| Lowery Frederick M.Executive Vice President · 24 transactions | — | 16.5K | 40.4K | — | 32.1K |
| Chai NelsonDirector · 6 transactions | +10.1% | 15.3K | 1.4K | 20 | 16 |
| Britt Lisa P.Sr. VP and Chief HR Officer · 31 transactions | -13.1% | 14.8K | 40.6K | — | 40.7K |
| Meyer JamesSr. Vice President & CFO · 1 transaction | — | 11.8K | — | — | — |
| Boxer Michael ASVP and General Counsel · 21 transactions | -17.4% | 10.8Kas of Mar 2025 | 24.0K | — | 24.3K |
| Harris C MartinDirector · 3 transactions | +17.3% | 9.5K | 1.4K | — | — |
| Jacks TylerDirector · 3 transactions | +17.4% | 9.5K | 1.4K | — | — |
| Sorensen Lars RebienDirector · 1 transaction | -1.3% | 9.2Kas of May 2024 | — | — | — |
| Shropshire Thomas B Jr.SVP and General Counsel · 3 transactions | — | 6.1K | 6.4K | — | — |
| Weisler Dion JDirector · 6 transactions | +28.6% | 5.4K | 1.4K | — | — |
| Chandy Ruby RDirector · 3 transactions | +68.1% | 3.5K | 1.4K | — | — |
| Mullen James CDirector · 2 transactions | +36.3% | 3.4Kas of May 2025 | 904 | — | — |
| Holmes Joseph R.VP & Chief Accounting Officer · 34 transactions | +95.7% | 3.1K | 3.0K | — | 1.2K |
| Spar Debora LDirector · 4 transactions | +90.4% | 2.6K | 1.4K | — | 164 |
| Keith R. AlexandraDirector · 3 transactions | +117% | 2.6K | 1.4K | — | — |
| Johnson Jennifer MDirector · 3 transactions | — | 1.4K | 1.4K | — | — |
| Lynch Karen SDirector · 3 transactions | — | 1.2K | 1.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -675.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.